Recent News

• 01.13.2026 - Letter to the Duchenne Community
• 01.13.2026 - Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101
• 01.12.2026 - Solid Biosciences Receives FDA Orphan Drug Designation for SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s Ataxia
• 01.12.2026 - Letter to the FA Community
• 01.12.2026 - Solid Biosciences Doses First Participant in First-in-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s Ataxia
• 01.05.2026 - Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 12.16.2025 - Solid Biosciences Announces Duchenne Muscular Dystrophy Added to National Recommended Uniform Screening Panel by the U.S. Department of Health and Human Services
• 12.01.2025 - Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 11.04.2025 - Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 11.03.2025 - Solid Biosciences Reports Third Quarter 2025 Financial Results and Provides Update on INSPIRE DUCHENNE Clinical Trial Progress and Planned Regulatory Discussions

Recent Filings

• 01.07.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.06.2026 - 4 Statement of changes in beneficial ownership of securities
• 12.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.03.2025 - 144 Report of proposed sale of securities
• 11.13.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.13.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.03.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]